Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Papillomavirus Infections 1Atypical Squamous Cells of the Cervix 1

Interventions

Paclitaxel 41Specimen Handling 36Carboplatin 34pembrolizumab 32Bevacizumab 32Magnetic Resonance Spectroscopy 29olaparib 19liposomal doxorubicin 16Cisplatin 16Biopsy 16Gemcitabine 15Taxes 12Nivolumab 12Immunoglobulin G 11Disulfides 11Cyclophosphamide 11Topotecan 10Doxorubicin 10fludarabine 9niraparib 7mirvetuximab soravtansine 7Fulvestrant 7trastuzumab deruxtecan 6palbociclib 6durvalumab 6Surveys and Questionnaires 6Megestrol Acetate 6lenvatinib 5dostarlimab 5Radiation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
epigallocatechin gallate × Gynecologic × 30 days × Clear all
NCT07572396 2026-05-14

Phase II Study of Dysplasixâ„¢ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities

Amplexd Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia, Papillomavirus Infections, Atypical Squamous Cells of the Cervix

Data powered by HemOnc (CC BY 4.0) Colophon âš¡